PALLAS, First-of-its-Kind Solid State UVB Medical Dermatology Laser Launched

LASEROPTEK's PALLAS Solid-State 311nm UVB Laser is Clinically- Proven & FDA Cleared to Treat Vitiligo, Psoriasis, Atopic Dermatitis and Leukodermas

PALLAS Solid-State 311nm UVB laser has been launched in the United States by LASEROPTEK Co., Ltd. The efficacious and safe PALLAS laser is FDA cleared for the treatment of vitiligo, psoriasis, atopic dermatitis, and leukoderma.

PALLAS is the fifth LASEROPTEK laser device to receive FDA clearance in the U.S. for dermatological treatments and brings to the U.S. market the world’s first solid-state UVB laser delivering efficacious and safer treatment for a variety of skin conditions that collectively affect close to a billion people worldwide.

PALLAS features unique technology improvements over 308 nanometer excimer lasers currently used to treat vitiligo, psoriasis, atopic dermatitis and leukodermas.  PALLAS provides physicians flexibility by allowing the choice of either 308 or 311 nanometer versions.  Both wavelength choices feature PALLAS’ unique, solid-state technology eliminating the need for costly and time-consuming excimer gas and electrode replacements no matter which wavelength is chosen.  This reduction in operating costs is a desired and welcomed benefit in today’s challenging market environment.

Dr. Peter Jenkin, owner of Dermatology Associates of Seattle since 2010, is a respected expert in the treatment of pigmentation related skin disorders and is among the first health care providers offering treatments using PALLAS.  “I chose LASEROPTEK’s PALLAS UVB laser with the 311nanometer output option given its efficacy and higher safety profile for my patients.  I had been aware of research for a few years that the 311nm wavelength might be the best option,” this according to Dr. Jenkin. “I also appreciate the solid-state technology that negates the need for costly and time-consuming service calls to replace electrodes and excimer gas,” added Dr. Jenkin.

Commenting on the launch of PALLAS in the U.S., CJ Lee, CEO of LASEROPTEK said, “LASEROPTEK, in collaboration with our U.S. partners Gale Force Aesthetics and Laser Service Solutions, is deeply committed to developing, selling and servicing advanced laser devices to the U.S. medical and cosmetic dermatology market that improve safety, efficacy and economics for our physician customers and their patients.  PALLAS is a great example of this commitment.  We very much appreciate Dr. Jenkin’s trust in PALLAS to provide his patients with safe, efficacious and comfortable treatments.  We look forward to a long-term relationship with Dr. Jenkin and the entire staff at Dermatology Associates of Seattle.”

Jayson Jonsson, CEO of Gale Force Aesthetics, the exclusive distributor of LASEROPTEK lasers in the U.S. adds, “We are excited and proud to partner with LASEROPTEK to launch PALLAS in the U.S.  Physicians need safe and effective treatment options for difficult-to-treat skin conditions like vitiligo, psoriasis, atopic dermatitis and leukodermas. We are confident that this device will provide a much-needed option to physicians and deliver great results for patients.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version